VARIABILITY IN AMINOGLYCOSIDE DOSING IN INTENSIVE CARE UNITS ACROSS LONDON - SHOULD OUR METHODS BE STANDARDISED? by JM Singleton et al.
POSTER PRESENTATION Open Access
Variability in aminoglycoside dosing in intensive
care units across London - should our methods
be standardised?
JM Singleton*, KE Grailey, JB Simon, JLC Wong
From ESICM LIVES 2015
Berlin, Germany. 3-7 October 2015
Introduction
Aminoglycoside doses are optimised to ensure adequate
peak levels are attained for the desired bactericidal
effect. Dose adjustments are increasingly realised to be
important in the critical care setting where pharmacoki-
netics of agents may vary [1]. Variables affecting dose
given include patient weight, renal function, dose per
unit weight and subsequent re-dosing schedule. It is
currently unclear if any dosing regime is superior.
Objectives
We assessed the availability of different aminoglycosides
in Intensive Care Units (ICUs) across London. We com-
pared the dosing and subsequent re-dosing regimes for
gentamicin, and surveyed the protocols for aminoglyco-
side use in renal replacement therapy (RRT).
Methods
A 7-part questionnaire was developed, and data collec-
tion was achieved by telephone interviews with Critical
Care Pharmacists at 27 London Hospitals between Feb-
ruary and April 2015.
Results
All 27 units had access to gentamicin with 23 (85%) of
the units using it as their first line aminoglycoside. 26 of
the 27 units also had access to amikacin but only 11
hospitals reported its use as regular.
The most common initial dosing regimen for gentami-
cin was 5mg/kg. Five ICUs (19%) used a higher initial
dosing regime of 7mg/kg.
Corrected body weight (CBW) calculations were
employed by 26 of the 27 ICUs to dose gentamicin for
obese patients. 19 ICUs defined obesity as an actual
body weight (ABW) of greater than 20% of patients’
IBW whilst 4 ICUs used a cut off of 15%. 3 ICUs
defined obesity using the body mass index (BMI) scale.
Maximum initial gentamicin doses ranged from 450mg
to 600mg and 5 ICUs had no maximum defined dose. 20
of the ICUs (75%) used trough levels to guide gentamicin
re-dosing and the remaining 7 (25%) used a nomogram.
14 ICUs (52%) had no specific protocols to guide dos-
ing for patients undergoing RRT. 10 ICUs (37%) dosed
these patients with a defined dose per kilogram (ranging
from 3 to 7mg/kg) and then used trough levels to guide
re-dosing. 2 units (7%) used three times a day dosing
and one unit reported they avoided gentamicin in RRT.
Conclusions
There is a large variation in the dose, maximum dose and
re-dosing of gentamicin across ICUs. Those patients
undergoing RRT have a wide variability in the total dose
that could potentially be administered. Further work
must be done to determine whether there are correla-
tions between the different dosing regimes and outcomes.
This preliminary work has highlighted the current ami-
noglycoside dose variability and we intend to further this
work by extending it across the United Kingdom.
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